Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Chem Rev. 2009 Jul;109(7):3125–3140. doi: 10.1021/cr900048k

Table 2. Clinical Trials Using Oncolytic Viruses for the Treatment of Malignant Gliomasa.

OV virus genetic alteration patients route of delivery highest dose median survival months) ref
G207 HSV-1 (strain F) deletion of both γ34.5 copies and disruption of ICP6/RR 21 i.t. 1 × 109 pfu 6 31
6 2 doses: i.t. and I.A.B. post-tumor resection 1.15 × 109 pfu 6.6 32
1716 HSV-1 (Glasgow strain 17) deletion of both γ34.5 copies 9 i.t. 1 × 105 pfu NI 33
12 i.t. 4–9 days prior to resection 1 × 105 pfu NI 34
12 IAB post-tumor resection 1 × 105 pfu NI 35
ONYX-015 adenovirus deleted E1B gene 24 IAB post-tumor resection 1 × 1010 pfu 6 36
NDV-HuJ Newcastle disease virus none 14 iv 55 BIU 8 37
reolysin reovirus none 12 i.t 1 × 109 pfu 5 38
a

Legend: BIU, billion infectious units; IAB., injected into adjacent brain; i.t., intratumoral; iv, intravenous; NI, not included; pfu, plaque-forming units.